Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

11.29USD
26 Jul 2016
Change (% chg)

$-0.09 (-0.79%)
Prev Close
$11.38
Open
$11.33
Day's High
$11.34
Day's Low
$11.06
Volume
10,244
Avg. Vol
201,847
52-wk High
$23.60
52-wk Low
$7.86

MNTA.OQ

Chart for MNTA.OQ

About

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox... (more)

Overall

Beta: 1.91
Market Cap(Mil.): $807.02
Shares Outstanding(Mil.): 70.92
Dividend: --
Yield (%): --

Financials

  MNTA.OQ Industry Sector
P/E (TTM): -- 41.28 37.71
EPS (TTM): -1.26 -- --
ROI: -26.90 -9.20 14.43
ROE: -30.08 -9.24 15.61

BRIEF-Momenta Pharmaceuticals appoints Steven Gilman to board of directors

* Momenta pharmaceuticals appoints steven c. Gilman, ph.d. To board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 23 2016

Momenta, Sandoz allowed to broaden claims over quality test patent

A federal judge has allowed Momenta Pharmaceuticals and Sandoz Inc to broaden a lawsuit accusing Amphastar Pharmaceuticals of infringing a patent on quality control methods used in making the blood thinner enoxaparin, the generic form of French drug maker Sanofi's Lovenox.

Jun 23 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.